Roche Palo Alto LLC

Syntex (u.s.a.) Inc.

Other

F. Hoffmann-la Roche Ag

David Bruce Repke

Ralph New Harris, Iii

Russell Stephen Stabler

James M Kress

Robin D Clark

Robert J Greenhouse

Lawrence Emerson Fisher

Hans Maag

Saul Jaime-Figueroa

Charles Alois Dvorak

Keena Lynn Green

Anthony Prince

Keith Adrian Walker

Nancy Elisabeth Krauss

Roger L Whiting

David John Morgans, Jr

Michael Patrick Dillon

Jurg R Pfister

Francisco Javier Lopez-Tapia

Colin C Beard

Todd Richard Elworthy

Christine E Brotherton-Pleiss

Clara Jeou Jen Lin

Douglas L Wren

Keith Adrian Murray Walker

Joan Marie Caroon

Bradley E Loe

Helen Y Wu

David E Clarke

David George Putman

Gregory R Martinez

Owen W Gooding

Pankaj D Rege

Philip J Teitelbaum

Eric Brian Sjorgren

Philip Jay Teitelbaum

Gregory Ricardo Martinez

Andrew John Briggs

Sharathchandra Surendra Hegde

Robert Greenhouse

Ralph New Harris

Iii Ralph New Harris

Russel Stephen Stabler

Ralph New Harris Iii

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, p, q, Ar, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Tetralin and indane derivatives and uses thereof

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R, R, and Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

[1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators

Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof,wherein m, n, q, Ar, R, R, R, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.

Compounds of the formula I: or pharmaceutically acceptable salts thereof,

Arylsulfonamidyl tetralin derivatives and uses thereof

The invention provides compounds of the formula: and pharmaceutically acceptable salts or prodrugs thereof, wherein m, p, q, r, A, E, X, Y, R, R, R, R, R, R, Rand are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

Quinolinone derivatives and uses thereof

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Heterocyclylakylamines as muscarinic receptor antagonists

Compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein m, Ar, R, R, and Rare as defined herein. The invention also provides methods for preparing, coompositions comprising, and methods for using compounds of Formula 1 for treatment of central nervous system disorders.

Aryloxy quinolines and uses thereof

Compounds of the Formula I: wherein m, n, k, A, X, Y, Z, Ar, R, R, R, and Rare as defined herein. The compounds are useful as 5-HT6 receptor antagonists. Also provided are compositions comprising, methods of using, and methods of making the subject compounds.

Dibenzoxazepinone derivatives and uses thereof

Heterocyclylalkylamines as muscarinic receptor antagonists

Growing community of inventors

Milpitas, CA, United States of America

David Bruce Repke